Favorable selection led to Medicare Advantage overpayments on the order of 14.4% in 2020.
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.
USC Schaeffer white paper finds that increasing access to obesity treatments would help save lives and reduce healthcare costs.
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
This paper examines how direct-to-consumer advertising (DTCA) for prescription drugs influences utilization by exploiting a large and plausibly exogenous shock to DTCA driven by the introduction of Medicare Part D.
Medicare Advantage plans have seen a more than 300% increase in enrollment—with payment policy yet to catch up.
Between 2006 and 2022, traditional Medicare enrollment declined by 3% while adjusted Medicare Advantage enrollment increased by 337%.